A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo

Launched by PEKING UNIVERSITY THIRD HOSPITAL ·

Keywords

ClinConnect Summary

This clinical trial is studying how well a medication called ruxolitinib cream works for treating vitiligo, a skin condition that causes loss of skin color in patches. Vitiligo can affect any part of the body and often impacts people’s quality of life. While there are several treatments available, they do not always work well and the condition can come back. This study aims to understand what factors might affect how effective ruxolitinib cream is when used in real-life settings.

The trial is open to people of all genders who have vitiligo, but more specific details about age or other requirements will be provided when the study begins recruiting. Participants who join can expect to use ruxolitinib cream as part of their treatment, and researchers will monitor how well the cream works for them. This study is important because it looks at how this treatment performs outside of strict clinical conditions, which can help doctors better understand who might benefit most from it. Currently, the study is not yet recruiting participants.

Gender

ALL

Eligibility criteria